111.00p-2.00 (-1.77%)26 Feb 2021, 17:05
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Reneuron Group PLC Fundamentals

Company NameReneuron Group PLCLast Updated2021-02-26
Shares in Issue56.856 mMarket Cap£63.11 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.35EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0515Debt Equity Ratio0.0958
Asset Equity Ratio2.3246Cash Equity Ratio1.4735
Quick Ratio1.3016Current Ratio1.77
Price To Book Value9.5238ROCE0

Reneuron Group PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Reneuron Group PLC Company Financials

Tangible Assets£1.04 m£1.34 m£1.48 m
Intangible Assets£186,000.00£186,000.00£186,000.00
Total Fixed Assets£1.23 m£1.52 m£1.67 m
Debtors£696,000.00£834,000.00£1.28 m
Cash & Equivalents£12.63 m£26.39 m£37.41 m
Other Assets000
Total Assets£20.38 m£31.51 m£43.37 m
Creditors within 1 year£6.45 m£7.40 m£5.85 m
Creditors after 1 year£707,000.00£864,000.00£968,000.00
Other Liabilities000
Total Liabilities£7.15 m£8.27 m£6.82 m
Net assets£13.22 m£23.24 m£36.55 m
Called up share capital£318,000.00£316,000.00£316,000.00
Share Premium£138.18 m£138.00 m£138.00 m
Profit / Loss-£13.86 m-£17.23 m-£20.97 m
Other Equity£13.22 m£23.24 m£36.55 m
Preference & Minorities000
Total Capital Employed£13.22 m£23.24 m£36.55 m
Debt Ratio£0.05£0.04£0.03
Assets / Equity2.32462.32462.3246
Cash / Equity1.47351.47351.4735
Cash Flow202020192018
Cash from operating activities-£14.30 m-£11.95 m-£14.89 m
Cashflow before financing-£7.99 m-£7.58 m-£362,000.00
Increase in Cash-£7.81 m-£7.48 m-£214,000.00
Turnover£6.07 m£49,000.00£43,000.00
Cost of sales000
Gross Profit000
Operating Profit-£14.41 m-£18.30 m-£20.38 m
Pre-Tax profit-£13.86 m-£17.23 m-£20.97 m

Reneuron Group PLC Company Background

ActivitiesReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
Latest Interim Date24 Nov 2020
Latest Fiscal Year End Date20 Jul 2020

Reneuron Group PLC Directors

2020-09-10Mr. John E. BerrimanNon-Executive Director,Chairman
2020-08-21Mr. Mark James DochertyNon-Executive Director
2013-08-15Professor Trevor Mervyn Jones CBENon-Executive Director
2020-08-21Dr. John David SindenExecutive Director,Chief Scientific Officer
2018-07-31Dr. Paul Bernard HarperNon-Executive Director
2020-08-21Mr. Bryan Geoffrey MortonNon-Executive Director,Chairman
2021-02-11Sir Christopher Thomas Evans OBENon-Executive Director
2020-09-10Mr. Simon C CartmellNon-Executive Director
2021-02-11Mr. Michael Elliott HuntExecutive Director,Chief Financial Officer and Company Secretary
2021-02-11Dr. Tim CornNon-Executive Director,Chairman
2021-02-11Mr. Olav HelleboExecutive Director,Chief Executive Officer
2021-02-11Dr. Michael John OwenNon-Executive Director
2020-09-10Dr. Claudia D'AugustaNon-Executive Director
2020-12-15Mr. Mark EvansNon-Executive Director

Reneuron Group PLC Contact Details

Company NameReNeuron Group PLC
AddressPencoed Business Park, Pencoed, CF35 5HY
Telephone+44 2038198400

Reneuron Group PLC Advisors

StockbrokerN+1 Singer
Phone+44 2074963000
Fax+44 2074963150
Nominated AdviserStifel Nicolaus Europe Ltd
Phone+44 2077107600
Fax+44 2077107609
StockbrokerStifel Nicolaus Europe Ltd
Phone+44 2077107600
Fax+44 2077107609
Financial PR AdviserBuchanan
Phone+44 2074665000
Fax+44 2074665001
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
SolicitorCovington & Burling LLP
Phone+44 2070672000
Fax +44 2070672222
StockbrokerMatrix Corporate Capital LLP
Phone(020) 3206 7000
Fax(020) 3206 7016
BankBarclays Bank PLC